Please assess the completion status of the following clinical trial:

Trial Title: Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Parkinson's disease (ie, takes Levodopa (L-DOPA))~* Hoehn and Yahr stage score of 2 to 4~* Subject has sleep-maintenance insomnia~Exclusion Criteria:~* Significant skin disease that would make transdermal drug use inappropriate~* Subject received therapy with controlled-release Levodopa (L-DOPA), entacapone or Stalevo® within 28 days prior to the Baseline Visit or has received therapy with Tolcapone~* Atypical Parkinsonian syndromes~* Previous diagnosis of Narcolepsy, Sleep Apnoea Syndrome, significant Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD), moderate to severe Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Transdermal Patches
- Rotigotine (Type: EXPERIMENTAL): Rotigotine Transdermal Patches

Based on this trial design, predict the completion outcome and termination type (if applicable).